BRIDGING DISCIPLINES:
ADVANCES IN THE COMPREHENSIVE
Management of Non-Small Cell Lung Cancer

Date: 20th November 2025
Time: 7 PM – 8:30 PM EAT

(CPD ACCREDITED)

Moderator

Dr. Muhindi Wanjugu
Physician and Chest Specialist, The Nairobi Hospital, Doctors Plaza, Nairobi

Speakers

Dr. Nuruddin Jooma
Haemato-Oncologist, Florida Cancer Specialists & Research Institute, USA
Systemic Therapy Advances in Non-Small-Cell Lung Cancer

Dr. Morris Muhinga
Consultant Cardiothoracic Surgeon, The Nairobi Hospital
Shift in Surgical Paradigm

Summary:

Lung Cancer: Contemporary Clinical Management and Emerging Evidence

Presentations by Dr Nuruddin Jooma and Dr Morris Muhinga

The sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing.

Key clinical principles discussed included optimal diagnostic pathways incorporating imaging, histopathology and immunohistochemistry, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection, avoid inappropriate use of immunotherapy and improve survival outcomes.

Current standards of care were reviewed across disease stages, including surgical management in early-stage disease, the expanding role of neoadjuvant and adjuvant systemic therapies, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms.

Both presentations reinforced the need for timely diagnosis, biomarker-driven treatment decisions and coordinated multidisciplinary care, while acknowledging ongoing challenges related to access, treatment sequencing and long-term disease control.

Key takeaway: Optimal lung cancer outcomes depend on precise staging, comprehensive molecular testing and evidence-based, multidisciplinary treatment across the disease continuum.